TAD-SIE:使用趋势自适应设计与合成干预估计器的临床随机对照试验样本量估计
针对3期随机对照试验因样本量不足导致30-40%失败的问题,提出TAD-SIE算法,利用合成干预估计个体治疗效果并模拟交叉设计,配合趋势自适应设计估计样本量。在真实3期双平行组优效性试验中,TAD-SIE获得63%至84%把握度和3%至6%显著性水平,优于基线算法的最佳49%把握度和6%显著性水平。
要点
- TAD-SIE通过合成干预模拟交叉设计,帮助平行组试验在样本量限制内达到目标把握度。
- 在真实3期双平行组优效性试验中,TAD-SIE获得63%至84%把握度和3%至6%显著性水平。
- TAD-SIE仅适用于主要结局可快速测量的试验,因其序贯性质。
核心结论
- TAD-SIE是一种优越的趋势自适应设计,可用于达到典型目标操作点,但仅适用于主要结局可快速测量的试验。
研究设计与样本
- 研究提出TAD-SIE算法,用于平行组试验的样本量估计,并在一个真实3期双平行组优效性试验(每组受试者数相等)上评估。
主要发现
- 在真实3期双平行组优效性试验中,TAD-SIE获得63%至84%把握度和3%至6%显著性水平。
- 基线算法最多获得49%把握度和6%显著性水平。
临床怎么用
- 作者认为TAD-SIE框架对有兴趣利用合成干预算法进行研究设计的实践者有用。
局限性
- TAD-SIE仅适用于主要结局可快速测量的试验,因其序贯性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phase-3 clinical trials provide the highest level of evidence on drug safety and effectiveness needed for market approval by implementing large randomized controlled trials (RCTs). However, 30-40% of these trials fail mainly because such studies have inadequate sample sizes, stemming from the inability to obtain accurate initial estimates of average treatment effect parameters. METHODS: To remove this obstacle from the drug development cycle, we present a new algorithm called Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator (TAD-SIE) that powers a parallel-group trial, a standard RCT design, by leveraging a state-of-the-art hypothesis testing strategy and a novel trend-adaptive design (TAD). Specifically, TAD-SIE uses synthetic intervention (SI) to estimate individual treatment effects and thereby simulate a cross-over design, which makes it easier for a trial to reach target power within trial constraints (e.g., sample size limits). To estimate sample sizes, TAD-SIE implements a new TAD tailored to SI given that using it violates assumptions under standard TADs. In addition, our TAD overcomes the ineffectiveness of standard TADs by allowing sample sizes to be increased across iterations without any condition while controlling significance level with futility stopping. Our TAD also introduces a hyperparameter that enables trial designers to trade off between accuracy and efficiency (sample size and number of iterations) of the solution. RESULTS: On a real-world Phase-3 clinical RCT (i.e., a two-arm parallel-group superiority trial with an equal number of subjects per arm), TAD-SIE obtains operating points ranging between 63% to 84% power and 3% to 6% significance level in contrast to baseline algorithms that get at best 49% power and 6% significance level. CONCLUSION: TAD-SIE is a superior TAD that can be used to reach typical target operating points but only for trials with rapidly measurable primary outcomes due to its sequential nature. The framework is useful to practitioners interested in leveraging the SI algorithm for their study design.
引用
- Lala S, Jha NK. TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator. Trials. 2025. PMID: 39881374. doi:10.1186/s13063-024-08661-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。